Semaglutide, Naltrexone/Bupropion, Phentermine/Topiramate to be evaluated for individualized obesity treatment in bipolar disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Abstract
A new clinical trial will assess individualized anti-obesity medication (AOM) strategies, including Semaglutide, in patients with bipolar disorder to optimize weight loss.